Dual drug composition, capsule drug, tablet drug and application of dual drug composition

Abstract

The invention relates to a treatment of myocardial necrosis caused by myocardial ischemia and anoxia caused by cardiovascular clogging caused by coronary atherosclerosis in the coronary heart disease,and provides a new practical dual drug composition for addressing both symptoms and root causes other than surgery and application of the dual drug composition. The dual drug composition comprises plant extracts of lithospermic acid B and salidroside. The binary drug composition is applied to prepare drugs for drug pass for treating coronary artery. The dual drug composition disclosed by the invention achieves the drug pass effect by opening and promoting collateral circulation, and addresses both symptoms and root causes, is simple to take, and solves all short-term and long-term problems inrevascularization treatment at present.

Description

technical field [0001] The invention relates, in particular, to a binary drug composition, capsule drug, tablet drug and application thereof which can be used as coronary artery drug bypass. Background technique [0002] <1> Cardiovascular disease is one of the main causes of death in developed countries, and according to the estimates of the United Nations in 2010 / 2011, it may become the leading cause of human death in the world. In 2018, the annual death toll caused by this disease was almost twice that of cancer. [0003] At present, there are more than 12 million people in the United States suffering from coronary heart disease, and more than one million revascularization operations are performed every year, and nearly 400,000 people die of coronary heart disease every year. According to statistics in 2018, the number of coronary heart disease in my country is more than 13 million, and the mortality rate accounts for more than 40% of the residents' disease mortali...

AI Technical Summary

Problems solved by technology

[0010] (3) Stent intervention in revascularization (BMS in PCI) was first performed by French doctors Jacques puel and Ulrich Sigwart in 1986 with non-coated stents, but the restenosis rate was as high as 30% in 6 months after surgery -50%, and the drug-eluting stent (DES) introduced later can reduce the restenosis rate, but it is also between 9-14%, and its long-term risk of thrombosis increases. Putting in a stent, a stent is a foreign body outside the body, and its long-term risk is difficult to estimate

[0011] (4) Other bioabsorbable scaffolds, stem cell transplantation, plaque atherectomy, rotational atherectomy, etc. have many imperfections, or high risk and difficult to control, so they have not been widely used

[0012] (5) Drug therapy. At present, Western drug therapy is mainly effective in regulating lipids and preventing thrombosis, but in terms of prevention, it can only delay the formation of plaques, but cannot prevent the formation of atherosclerotic plaques. incapable of eradication

[0029] (1) The route and method of administration

[0030] (2) Safety issues: the promotion of collateral circulation affects angiogenesis and growth, which may promote the progression of tumors and coronary atherosclerotic plaques in the body, and increase the occurrence of plaque instability and other problems

However, VEGF165, which is soluble and can be combined with proteoglycans, has been used as a growth factor, but its biological half-life is short (less than 6 minutes), and its curative effect is short. Therefore, repeated administration is required, and the route of administration is troublesome and expensive. allergic reaction rate is also high

At present, many genes regulated by HIF-1α have been found, such as vascular endothelial cell growth factor, interleukin-8 (IL-8), platelet-derived endothelial cell growth factor (PDECGF), FSP-1 (Thrombos Pondis-1) , and inducible nitric oxide synthase (iNOS), etc., but many are still under study

Images